Skip to main content


Dynamic Biomimetics for Cancer Immunotherapy (DBCI)

The “Dynamic Biomimetics for Cancer Immunotherapy” group started as a Max Planck Partner Group in 2017 funded by the Max Planck Society (Germany).

Currently, it focuses on the design, synthesis, and fabrication of bioinspired materials, especially artificial extracellular matrixes, for biomedical applications. In particular, we are mostly dedicated to the oncology field by developing patient-derived cancer organoids and new methodologies related to the cellular manufacture processes for cancer immunotherapies.

Permanent Scientific Researchers

Guasch Camell, Judit [Tenured Scientist-CT]
Max Planck Partner Group Leader

Postdoctoral & Project Researchers